How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. Blood cancer discovery Ribas, A., Dhodapkar, M. V., Campbell, K. M., Davies, F. E., Gore, S. D., Levy, R., Greenberger, L. M. 2021; 2 (6): 562-567


Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and to foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy.

View details for DOI 10.1158/2643-3230.BCD-21-0166

View details for PubMedID 34778796

View details for PubMedCentralID PMC8580613